Kaken Pharmaceutical : Reference Data of Financial Statements for the 3Q of Fiscal 2022

Consolidated Financial Results for the Third Quarter of Fiscal 2022

(Reference Data of Consolidated Financial Results)

February 3, 2023

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: [phone]

Fax: [phone]

Email: [e-mail]

1. Summary of Consolidated Financial Statements for the Third Quarter of Fiscal 2022
				(amounts are rounded down to the nearest million Yen)
	FY2021	FY2021	FY2022	Change		Plan	Change
	3Q	3Q	Yen	%	FY2022	Yen	%
Net sales	57,708	76,034	55,573	(2,135)	96.3%	73,500	(2,534)	96.7%
Operating profit	13,889	17,064	12,394	(1,495)	89.2%	7,500	(9,564)	44.0%
Ratio to net sales	24.1%	22.4%	22.3%			10.2%
Ordinary profit	14,322	17,542	12,976	(1,346)	90.6%	8,100	(9,442)	46.2%
Ratio to net sales	24.8%	23.1%	23.3%			11.0%
Profit	10,246	9,549	9,149	(1,096)	89.3%	6,100	(3,449)	63.9%
Ratio to net sales	17.8%	12.6%	16.5%			8.3%
Comprehensive income	10,930	9,563	9,343	(1,587)	85.5%
R&D expenses	6,035	8,420	6,310	274	104.6%	16,600	8,180	197.1%

2. Sales of Main Pharmaceuticals and Medical Devices (non-consolidated)
			(amounts are rounded down to the nearest million Yen)
	FY2021		FY2022	Change	Revised	Change	Plan
	FY2021	plan
	3Q	3Q	(%)	(%)	FY2022
		FY2022
Onychomycosis treatment	14,764	18,449	14,444	97.8%	18,100	98.1%	18,300
Clenafin
Anti-osteoarthritis agent	14,741	18,853	13,159	89.3%	17,300	91.8%	17,600
Artz
Post-operative
anti-adhesive	6,631	8,433	6,095	91.9%	7,900	93.7%	8,600
Seprafilm
Wound-healing agent	2,088	2,769	2,075	99.4%	2,800	101.1%	2,900
Fiblast
Anti-dysuria	1,505	1,936	1,445	96.0%	2,000	103.3%	2,000
Ebrantil
Primary axillary
hyperhydrosis treatment	760	950	1,049	138.0%	1,400	147.4%	1,600
Ecclock
Periodontal
regenerative agent	659	860	670	101.6%	1,000	116.3%	1,000
Regroth
Lumber disc
herniation treatment	306	381	303	99.0%	400	105.0%	500
Hernicore
Generic products (total)	6,884	8,831	6,375	92.6%	8,000	90.6%	9,300

3. Products under Development

Development	Planned
Code	Indication

Development

Stage

Remarks

KAR

ART-001

ART-648

BBI-4000

KP-483

NM26-2198

Development Code

(Product Name)

KMW-1 (NexoBrid®)

Head lice

Refractory vascular malformations

Bullous pemphigoid

Primary palmoplantar hyperhydrosis

Solid tumors (immune-oncology)

Atopic dermatitis

Indication

partial- and full-thickness burns

• III
  P II
  P II
  P I
  P I
  P I

Status

Approved

(December 2022)

In-licensed from Arbor Pharmaceuticals, LLC Product name outside Japan: Sklice®

Development project of ARTham Therapeutics Inc.

Development project of

ARTham Therapeutics Inc.

Additional indication of Ecclock, which has been approved for primary axillary hyperhydrosis treatment

Product from in-house drug discovery

Preparing for Phase I clinical trial Co-development with Numab Therapeutics AG

Remarks

In-licensed from MediWound Ltd. Product name outside Japan: NexoBrid®